Egetis Therapeutics
Develops and commercializes drugs for serious rare diseases with unmet medical needs.
EGTX | ST
Overview
Corporate Details
- ISIN(s):
- SE0003815604
- LEI:
- 549300RZCKGWRUBPMY22
- Country:
- Sweden
- Address:
- Klara Norra Kyrkogata 26, 111 22 Stockholm
- Website:
- https://www.egetis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Egetis Therapeutics is an innovative and integrated pharmaceutical company focused on developing and commercializing treatments for serious, rare diseases with significant unmet medical needs. The company's strategy centers on advancing projects through late-stage clinical development to regulatory approval and market launch. Its leading drug candidate, Emcitate, targets MCT8 deficiency, a rare genetic disease characterized by a shortage of thyroid hormones in the brain.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Egetis Therapeutics and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-21 07:00 |
Interim Report
|
Swedish | 3.7 MB | |
| 2025-08-21 07:00 |
Interim Report
|
English | 3.4 MB | |
| 2025-07-15 08:00 |
Regulatory News Service
Egetis receives FDA Breakthrough Therapy Designation for tiratricol for MCT8 de…
|
English | 75.2 KB | |
| 2025-07-15 08:00 |
Legal Proceedings Report
Egetis erhåller Breakthrough Therapy Designation från FDA för tiratricol för be…
|
Swedish | 71.1 KB | |
| 2025-05-16 00:00 |
Annual Report (ESEF)
|
Swedish | 12.4 MB | |
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Kommuniké från Egetis Therapeutics årsstämma 2025
|
Swedish | 55.3 KB | |
| 2025-05-06 17:59 |
Post-Annual General Meeting Information
Bulletin from Egetis Therapeutics’ Annual General Meeting 2025
|
English | 52.3 KB | |
| 2025-04-30 07:00 |
Quarterly Report
|
Swedish | 3.7 MB | |
| 2025-04-30 07:00 |
Earnings Release
|
English | 3.3 MB | |
| 2025-02-26 07:00 |
Earnings Release
|
Swedish | 735.2 KB | |
| 2025-02-26 07:00 |
Annual Report
|
English | 764.5 KB | |
| 2025-02-13 15:25 |
Legal Proceedings Report
European Commission approves Egetis’ Emcitate® (tiratricol) as the first and on…
|
English | 73.3 KB | |
| 2025-02-13 15:25 |
Legal Proceedings Report
EU-kommissionen godkänner Egetis Emcitate® (tiratricol) som den första och enda…
|
Swedish | 74.4 KB | |
| 2024-12-30 16:42 |
Share Issue/Capital Change
Change in the number of shares and votes in Egetis Therapeutics
|
English | 59.0 KB | |
| 2024-12-30 16:42 |
Share Issue/Capital Change
Ändring av antalet aktier och röster i Egetis Therapeutics
|
Swedish | 65.1 KB |
Automate Your Workflow. Get a real-time feed of all Egetis Therapeutics filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Egetis Therapeutics via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2021-08-19 | Henrik Krook | Other | Buy | 31,045 | 167,332.55 SEK |
| 2021-07-01 | Henrik Krook | Other | Buy | 8,000 | 44,800.00 SEK |
| 2021-06-30 | Henrik Krook | Other | Buy | 27,000 | 151,578.00 SEK |
| 2021-06-09 | Kristina Sjöblom Nygren | Other | Buy | 2,000 | 12,120.00 SEK |
| 2021-05-10 | Yilmaz Mahshid | Other | Buy | 30,194 | 183,277.58 SEK |
| 2021-04-28 | Henrik Krook | Other | Buy | 30,000 | 187,800.00 SEK |
| 2020-11-23 | Nicklas Westerholm | Other | Buy | 11,425 | 59,981.25 SEK |
| 2020-03-06 | Nicklas Westerholm | Other | Buy | 16,000 | 102,400.00 SEK |
| 2020-03-06 | Yilmaz Mahshid | Other | Buy | 16,000 | 102,240.00 SEK |
